Active substance
Hexoprenaline
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| IPRADOL 0.5 MG. TABLETS | 0.5 mg | Tablet · Oral use | 20 Blister | SAR 7.20 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
| IPRADOL 0.5 MG. TABLETS | 0.5 mg | Tablet · Oral use | 100 Blister | SAR 22.75 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
| IPRADOL AEROSOL | 3 mg/ml | Inhalation vapour · Inhalation use | 1 Bottle | SAR 33.00 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
| IPRADOL AMPULES 5MCG-2 ML | 2.5 µ/ml | Injection · Intravenous use | 5 Ampoule | SAR 7.20 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.